文献速递头颈外科咽喉与嗓音

晚期喉癌患者采用个体化生物选择治疗方法的生存率

Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2017-01-01

该研究纳入2002至2012年某学术机构的247例喉癌患者,评估单周期新辅助化疗生物选择后行喉切除术或同步放化疗能否改善生存。全队列5年总生存率和疾病特异性生存率分别为75%和83%;晚期患者中新辅助化疗组疾病特异性生存率优于同步放化疗组(HR 0.48),手术组生存率亦较高。

要点

  • 全队列5年总生存率75%,疾病特异性生存率83%。
  • 晚期患者中新辅助化疗组疾病特异性生存率优于同步放化疗组(HR 0.48)。
  • 手术组5年疾病特异性生存率91%,同步放化疗组66%。

核心结论

  • 采用单周期新辅助化疗的生物选择治疗方法可获得更优的生存率。
  • 选择原发手术的患者也获得良好生存率,新辅助化疗和原发手术均优于同步放化疗的生存率。
  • 晚期喉癌的最佳个体化治疗方法尚未确定。

研究设计与样本

  • 在某学术机构开展的非选择性队列研究,纳入2002年至2012年的247例喉癌患者。
  • 局限期(I和II期)患者接受内镜下切除、放疗或对深部浸润T2病变行放化疗。
  • 晚期(III和IV期)患者推荐接受新辅助化疗、同步放化疗或原发手术。
  • 中位随访48个月;研究于2002年1月1日至2012年12月31日进行,数据分析于2015年12月1日完成。

主要发现

  • 247例患者中191例(77.3%)为男性,平均(标准差)年龄59.6(10.4)岁。
  • 94例局限期患者中,33例(35.1%)接受内镜下切除,50例(53.2%)接受单纯放疗,11例(11.7%)因深部浸润T2病变接受放化疗。
  • 153例晚期患者中,71例(46.4%)接受新辅助化疗,50例(32.7%)接受同步放化疗,32例(20.9%)接受手术。
  • 全队列5年总生存率和疾病特异性生存率分别为75%(95%CI,68%-81%)和83%(95%CI,77%-88%)。
  • I或II期患者疾病特异性生存率为92%(95%CI,83%-97%),III或IV期患者为78%(95%CI,69%-84%)。

关键数值与推荐

  • 倾向性校正的多变量分析控制已知预后因素后,新辅助化疗组疾病特异性生存率较放化疗组显著改善(风险比[HR],0.48;95%CI,0.29-0.80)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Use of chemoradiotherapy for advanced laryngeal cancer led to a major shift in treatment as an alternative to laryngectomy. Despite widespread adoption of chemoradiotherapy, survival rates have not improved and the original premise of matching neoadjuvant chemotherapy tumor response to determine subsequent treatment has not been followed. OBJECTIVE: To determine whether improved survival could be achieved by incorporating a single cycle of neoadjuvant chemotherapy to select patients with advanced disease for either laryngectomy or concurrent chemoradiotherapy. DESIGN, SETTING, AND PARTICIPANTS: An unselected cohort of 247 patients with laryngeal cancer in an academic institution between 2002 and 2012 was evaluated. Patients with limited disease (stages I and II) underwent endoscopic resection, radiotherapy, or chemoradiotherapy for deeply invasive T2 lesions. For patients with advanced disease (stages III and IV), neoadjuvant chemotherapy, concurrent chemoradiotherapy, or primary surgery was recommended. Overall survival (OS) and disease-specific survival (DSS) were analyzed. Median follow-up was 48 months. The study was conducted from January 1, 2002, to December 31, 2012; data analysis was completed December 1, 2015. INTERVENTIONS: Endoscopic resection, radiotherapy, chemoradiotherapy, neoadjuvant chemotherapy, concurrent chemoradiotherapy, and primary surgery. MAIN OUTCOMES AND MEASURES: Overall survival and DSS. RESULTS: Of the 247 patients, 191 (77.3%) were male; mean (SD) age was 59.6 (10.4) years. Of 94 patients with limited disease, 33 (35.1%) underwent endoscopic resection; 50 (53.2%), radiotherapy alone; and 11 (11.7%), chemoradiotherapy for deeply invasive T2 lesions. Of 153 patients with advanced disease, 71 (46.4%) received neoadjuvant chemotherapy; 50 (32.7%), concurrent chemoradiotherapy; and 32 (20.9%), surgery. Five-year OS and DSS was 75% (95% CI, 68%-81%) and 83% (95% CI, 77%-88%), respectively, for the entire cohort. The DSS was 92% (95% CI, 83%-97%) for patients with stage I or II and 78% (95% CI, 69%-84%) for patients with stage III or IV disease. For patients with advanced disease, 5-year OS and DSS ranged from 78% (95% CI, 55%-90%) and 91% (95% CI, 67%-98%), respectively, for surgery; to 76% (95% CI, 63%-85%) and 79% (95% CI, 67%-88%), respectively, for neoadjuvant bioselection; and to 61% (95% CI, 44%-75%) and 66% (95% CI, 48%-79%), respectively, for primary chemoradiotherapy. Propensity-adjusted, multivariable controlling for known prognostic factors DSS was significantly improved in the neoadjuvant group compared with the chemoradiotherapy group (hazard ratio [HR], 0.48; 95% CI, 0.29-0.80). CONCLUSIONS AND RELEVANCE: Superior survival rates were achieved with a bioselective treatment approach using a single cycle of neoadjuvant chemotherapy. Good survival rates were also achieved in patients selected for primary surgery, and both neoadjuvant chemotherapy and primary surgery were better than survival rates with concurrent chemoradiotherapy, suggesting that the optimal individualized treatment approach for patients with advanced laryngeal cancer has not yet been defined.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Wolf GT, Bellile E, Eisbruch A, et al. Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2017. PMID: 28152117. doi:10.1001/jamaoto.2016.3669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。